Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

European Journal of Cancer

Volumn 41, Issue 5, 2005, Pages 694-701

  Helle, S I ^a   Mietlowski, W ^b   Guastalla, J P ^c   Szakolczai, I ^d   Bajetta, E ^e   Sommer, H ^f   Baltali, E ^g   Pinter, T ^h   Csepreghy, M ⁱ   Ottestad, L ^j   Boni, C ^k   Bryce, C ^l   Klijn, J G M ^m   Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CENTRE LÉON BÉRARD   (France)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g HACETTEPE UNIVERSITY   (Turkey)

^h Endocrinology and Diabetology   (Hungary)

ⁱ UZSOKI HOSPITAL   (Hungary)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k S MARIA NUOVA HOSPITAL   (Italy)

^l Vancouver Cancer Centre   (Canada)

^m ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Breast cancer; IGF I; IGFBP 2; Octreotide; Tamoxifen

Indexed keywords

OCTREOTIDE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; WESTERN BLOTTING;

EID: 20044384178     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.015     Document Type: Article

References (27)

1. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
2. K.P. Karey, and D.A. Sirbasku Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol Cancer Res 48 1988 4083 4092
3. S.E. Hankinson, W.C. Willett, and G.A. Colditz Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1998 1393 1396
4. G. Weckbecker, L. Tolcsvai, and B. Stolz Somatotatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas Cancer Res 54 1994 6334 6337
5. B. Setyono-Han, M.S. Henkelman, and J.A. Foekens Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells Cancer Res 47 1987 1566 1570
6. R.B. Colletti, J.D. Roberts, and J.T. Devlin Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer Cancer Res 49 1989 1882 1884
7. S.I. Helle, J. Geisler, and J.P. Poulsen Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study Br J Cancer 78 1998 14 20
8. J.P. Parisot, K.S. Leeding, and X.F. Hu Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line Breast Cancer Res Treat 55 1999 231 242
9. A.J. Stewart, M.D. Johnson, and F.E. May Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells J Biol Chem 265 1990 21172 21178
10. M. Pollak Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues Digestion 57 Suppl. 1996 29 33
11. J.N. Ingle, V.J. Suman, and C.G. Kardinal A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma Cancer 85 1999 1284 1292
12. M. Bontenbal, J.A. Foekens, and S.W. Lamberts Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up Br J Cancer 77 1998 115 122
13. K. Kutz, E. Nuesch, and J. Rosenthaler Pharmacokinetics of SMS 201-995 in healthy subjects Scand J Gastroenterol Suppl 119 1986 65 72
14. E. Bajetta, G. Procopio, and L. Ferrari A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma Cancer 94 2002 299 304
15. V.J. Frost, S.I. Helle, and P.E. Lonning Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer J Clin Endocrinol Metab 81 1996 2216 2221
16. S.I. Helle, D. Ekse, and J.M. Holly The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids J Steroid Biochem Mol Biol 81 2002 95 102
17. S.T. Holm A simple sequentially rejective multiple test procedure Scand J Stat 6 1979 65 70
18. E. del Pozo, M. Neufeld, and K. Schluter Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration Acta Endocrinol (Copenh) 111 1986 433 439
19. P.E. Lonning, K. Hall, and A. Aakvaag Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients Cancer Res 52 1992 4719 4723
20. E.I. Lahti, M. Knip, and T.J. Laatikainen Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen Cancer 74 1994 618 624
21. J.F. Dorgan, C. Longcope, and C. Franz Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies J Natl Cancer Inst 94 2002 606 616
22. P.E. Lonning Aromatase inhibitors and inactivators for breast cancer therapy Drugs Aging 19 2002 277 298
23. P. Cohen, D.M. Peehl, and T.A. Stamey Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients J Clin Endocrinol Metab 76 1993 1031 1035
24. H.L. Muller, Y. Oh, and T. Lehrnbecher Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia J Clin Endocrinol Metab 79 1994 428 434
25. A.G. Renehan, J. Jones, and C.S. Potten Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer Br J Cancer 83 2000 1344 1350
26. S.I. Helle, T. Ueland, and D. Ekse The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy J Clin Endocrinol Metab 86 2001 227 233
27. A. Bereket, C.H. Lang, and S.L. Blethen Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young J Clin Endocrinol Metab 80 1995 3647 3652